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Treatment of rhinosinusitis and dry eye with 
an antibacterial honey nasal spray
Anita Perng, Julie Albietz, Kara Fung, Sheng Ho, Kevin Le, Katrina Leanne Schmid
ABSTRACT
Aim:  Chronic rhinosinusitis is an inflammatory disease of the nasal mucosa often occurring concurrently with dry eye. The 
aim was to assess the effects of Manuka (Leptospermum spp.) antibacterial honey nasal spray (Melcare® Manuka+™ 
Nasal Spray, Melcare, Australia) and eye drops (Optimel Manuka+ Dry Eye Drops, Melcare, Australia) on both conditions. 
The safety of and adherence to these treatments were also evaluated. Methods: Twenty-seven participants, aged 50 
to 77 years, with chronic rhinosinusitis and dry eye symptoms were recruited and randomised to two treatment groups; 
22 completed the study. One group used the Manuka Nasal Spray (n=10) and the other the Manuka Nasal Spray plus 
Manuka Dry Eye Drops (n=12); treatments were used twice daily for 4 weeks.  Before and after treatments symptoms 
were surveyed (SNOT-20, ODSI) and ocular surface assessed (bulbar and limbal conjunctival redness, non-invasive and 
fluorescein tear break up times, tear secretion, ocular surface staining). Participants completed a daily log of their usage 
of treatments and any issues experienced. Results: Both treatment groups showed significant improvements in nasal 
symptoms, and decreased surface staining. Participants using the Manuka+ Dry Eye Drops also had a reduction in their 
dry eye symptoms. There was no significant difference between the effects of the two treatments on ocular surface 
assessments. No adverse responses were reported to either treatment. Conclusions:  The Manuka+ Nasal Spray is 
effective in improving symptoms of chronic rhinosinusitis over a 4 week period, but must be used in conjunction with the 
Manuka+ Dry Eye Drops to improve concurrent dry eye symptoms.
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INTRODUCTION
Dry, red, sore, irritated eyes affect one in three adults 
[1]. Dry eye disease adversely affects our ability to see 
clearly, read comfortably, work productively and interact 
socially [2]. At its’ worst, dry eye disease adversely affects 
our quality of life and can lead to infection, scarring and 
permanent vision loss [3]. Dry eye conditions are often 
poorly responsive to conventional lubricant eye drops and 
eye lid hygiene treatments [4]. 
Between the ocular (eye) surface and the nose, the 
nasolacrimal apparatus is a direct physical connection of 
the ocular surface to the nasal mucosa (mucosa lining). 
The majority (75-85%) of the tears drain from the eye 
surface into the nasolacrimal sac and the nasolacrimal duct 
and empty into the nose. Additionally the eye and the nose 
are interconnected connected by neural (nerve) and venous 
(blood vessel) systems [5]. 
Chronic rhinosinusitis (CRS) is a prevalent and debilitating 
disease, comprising a spectrum of inflammatory and 
infectious diseases that concurrently affect both the nose 
and paranasal sinuses for longer than three months [6]. 
Like dry eye disease, CRS significantly impacts quality of 
life, and, not only causes significant physical symptoms, 
but also results in substantial functional and emotional 
impairment [7]. The prevalence of CRS is approximately 
10% to 15% [6] with dry eye symptoms reported by nearly 
70% of CRS sufferers [8]. Both CRS and dry eye involve 
inflammation of mucosal (mucous producing) surface 
tissue which may have a common immune mediated cause 
[6, 9]. Also, a lack of the aqueous component in the tears in 
dry eye disease and associated lack of antimicrobial proteins 
in the tears and increase in pro-inflammatory factors in dry 
eye might contribute to poor sinus drainage and bacterial 
overgrowth [8]. 
Treatment of CRS is primarily focused on reducing mucosal 
inflammation, removing bacterial infection/colonization, 
and improving sino-nasal function. Medical therapies 
used include nasal saline irrigation and saline sprays, nasal 
steroids, oral antibiotics and functional endoscopic sinus 
surgery in individuals with CRS non-responsive to medical 
treatment [10]. Some patients with CRS fail to respond to 
either conventional medical or surgical intervention [6,10], 
and hence alternative therapies are sought by patients and 
practitioners [10]. 
There is some evidence to suggest that honey, an anti-
microbial and anti-inflammatory agent may be beneficial as 
a safe, low-priced adjuvant therapy, to reduce inflammation 
and foster mucosal healing in patients suffering from 
chronic rhinosinusitis [11]. Honey does not have the side 
effects of chronic nasal steroid use, such as increased 
intraocular pressure and cataract formation [12] nor the 
resistance issues associated with repeated antibiotic dosing 
[13].
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In vitro evidence has indicated that Manuka honey is 
an effective agent for preventing Staphylococcal and 
Pseudomonas biofilm formation [14,15] and does not 
cause epithelial injury, inflammation or morphological 
changes to the tissue [16]. However, Manuka honey has yet 
to be definitively shown to be effective in the treatment in 
patients with CRS. An in vivo study by Thamboo et al. [17] 
evaluated Manuka honey nasal irrigation in patients with 
allergic fungal rhinosinusitis (fungal infection involving 
the nasal sinuses) and found a symptomatic improvement 
during treatment and a small subset of patients 
demonstrated a significant endoscopic improvement. 
Manuka Honey therefore has important clinical 
implications and could lead to a new approach for treating 
refractory (non-responsive) CRS. Presently there is only 
one clinical trial demonstrating safety and efficacy of a 
Thyme honey nasal spray in CRS [11] and one clinical 
trial using Manuka honey in CRS showing an absence of 
adverse effects and improvement in clinical symptoms 
[17].  Regulatory approved (Australian Therapeutics Goods 
Administration) antibacterial honey products (Optimel™ 
Manuka+ Dry Eye Drops  and Manuka+ Nasal Spray 
(Melcare Biomedical Pty Ltd, Australia) are available over 
the counter for external eye and nasal care. These products 
are prepared to a rigorous set of standards from a unique 
proprietary mix of honeys from the Australian and New 
Zealand Leptospermum species. These honeys are selected 
for their antibacterial activity, including activity against 
antibiotic resistant strains such as methicillin resistant 
Staphylococcus aureus and Pseudomonas aeruginosa [13,18-
21]. The aim of this study was to explore the efficacy of 
Manuka +™ Nasal Spray and Optimel™ Manuka+ Dry 
Eye Drops in the management of chronic rhinosinusitis 
and dry eye. 
MATERIALS AND METHODS
Participants
Twenty-seven participants between the ages of 50 and 
77 years, with a minimum 12 month history of chronic 
rhinosinusitis and dry eye symptoms, were recruited from 
the Queensland University of Technology Optometry 
Clinic. Exclusion criteria included an allergy or sensitivity 
to bee or honey products, current contact lens wear, 
current upper respiratory tract infections, nasolacrimal 
duct conditions, pre-existing corneal conditions, and 
recent eye surgery. The study complied with the tenets 
of the Declaration of Helsinki and was approved by the 
University’s Human Research Ethics Committee. 
Prior to recruitment, an instillation trial of each Optimel™ 
honey treatment product was performed to ensure that 
none of the participants were susceptible to hypersensitivity 
reactions; none had an allergic response. It was expected 
that the topical ocular use of honey would produce 
transient stinging and conjunctival inflammation [22] 
and that nasal use may produce a temporary but tolerable 
burning sensation [17]. If protracted inflammation and/or 
stinging/burning (more than 5 min) were experienced, or 
any late stage reactions were reported, the participant was 
excluded from further participation (no participants were 
excluded for these reasons). 
The data collection was performed between July 2015 and 
June 2016.  Five participants did not complete the trial 
for the following reasons: they were unable to attend the 
follow-up appointment for unrelated reasons (n=3), they 
developed a viral upper respiratory tract infection (n=1), 
or they acquired an unrelated systemic condition (n=1). 
Only the data of the 22 participants that completed the 
full 4-week treatment were included in the analysis (Table 
1). The mean age of participants were 66±8 years, 14 were 
females and 8 males. 
Table 1. Participant Characteristics at Baseline
Variable Total
Honey 
Nasal 
Spray
Honey Nasal 
Spray + Honey 
Eye Drops
Participants (n) 22 10 12
Average Age (year) 66±8 66±8 65±8
Gender (no. male/ 
female) 8/14 5/7 3/7
Treatments 
Participants were randomised to one of two treatment 
groups: i) Melcare® Manuka +™ Nasal Spray, and ii) 
Melcare® Manuka +™ Nasal Spray and Optimel Manuka+ 
Dry Eye Drops (Melcare, Australia). Both products are 
16.5% Leptospermum spp. Participants were instructed 
to use the nasal spray (1-2 sprays per nostril) twice daily 
(once in the morning and once in the afternoon) and if also 
provided the eye drops, told to use those twice a day also 
(one drop per eye in the inferior conjunctival sac).
All dry eye and nasal products were ceased at least two 
weeks prior to baseline measurements. It was not possible 
to mask the participants as to the treatment they were 
using as the participants had to self-administer treatments 
and the Manuka products have a unique look, smell and 
taste with nasolacrimal drainage. Before and after each 
treatment period nasal and dry eye symptomology, ocular 
surface inflammation, and tear quantity and quality were 
assessed. The researchers taking the measurements were 
masked as to the participant’s treatment allocation. During 
the treatment period participants completed a log detailing 
their usage of treatments and any issues experienced.
Measurements
Participants attended two measurement sessions (baseline, 
4 weeks). The study involved both a subjective assessment 
of nasal symptoms and subjective and objective assessments 
of dry eye. The validated Sino-Nasal Outcome Test (SNOT-
20) was used to assess nasal symptoms [23]. The validated 
Ocular Surface Disease Index (OSDI) [24], a validated 
dry eye questionnaire, was used to assess ocular surface 
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symptoms. Assessment of the tear film and ocular surface 
were performed objectively using the Keratograph5M 
(OCULUS Optikgeräte GmbH, Wetzlar, Germany). 
These assessments included limbal and bulbar conjunctival 
redness [25] and tear film stability (non-invasive tear break 
up time (NIKBUT) [26]. The Phenol-Red Thread test 
(PRT) [27] was used to measure tear secretion. Ocular 
surface staining was graded using the Oxford Scale [1] and 
fluorescein tear break up time (FBUT) [28] also measured.
The logbook required participants to record their use 
of the honey products and record any significant nasal, 
ocular, or systemic adverse events in their logbooks. Both 
groups could also use lubricant eye drops if required; 4-5 
participants in each group reported using ocular lubricants 
during the 4 week treatment phase. Compliance with the 
honey treatments were calculated from the log book as the 
number of applications actually performed divided by the 
number of prescribed applications converted to a percent.
Data Analysis 
The data of participant’s right eyes were selected for data 
analysis which was conducted using the data analysis 
program SPSS 17.0 for Windows (SPSS Inc, Chicago, 
Illinois, USA). Homogeneity of variance was assessed 
using Levene’s Test. Comparison between groups was 
conducted with parametric independent t-tests for SNOT-
20 and OSDI questionnaires, PRT, FBUT, NIKBUT. Non-
parametric Mann-Whitney U tests were used to analyse 
limbal and bulbar redness scores, and Oxford staining 
scores, as these measures are graded on a scale of 0-4. 
Treatment effects (baseline vs 4 weeks) within groups were 
analysed using the either parametric (paired t-test) or non-
parametric (Wilcoxon Signed Rank) tests as appropriate.  
RESULTS
Adherence
Self-reported adherence to the honey nasal spray when used 
alone was good to excellent in all participants; reported 
compliance was excellent in 60%, very good in 20%, and 
good in 20% (Table 2).  Adherence to the nasal spray 
reduced when both treatments were used concurrently; 
poor to fair in 42%. Adherence to the honey eye drops 
was good to excellent in 75% but fair to poor in the others 
(Table 2).  There were no reports of adverse reactions or 
issues reported in the daily logs. 
Baseline Data
Baseline data of the two group was similar except for nasal 
bulbar redness which was higher in the honey nasal spray 
group (p=0.014) (Table 3). Both groups had a moderate 
degree of sino-nasal symptomatology (SNOT-20 > 22.5) 
[29], and moderate to severe eye symptoms (OSDI =31 
for Honey Nasal Spray group (moderate symptoms) and 
OSDI =38 for the Honey Nasal Spray + Honey Eye Drops 
treatment group (severe symptoms). Phenol red thread test 
tear secretion was borderline for tear deficiency (≤10 mm / 
15 s is significant) [1]. Fluorescein tear break up and non-
invasive tear break up time were reduced,  indicating our 
participant cohort had tear film instability [1], and a mild 
to moderate degree of ocular surface staining was present 
[30]. 
Table 2. Compliance with Treatments.
Self- Reported Compliance 
Rating
Honey Nasal Spray alone 
(n=10)
Honey Nasal Spray
in combination  (n=12)
Honey Eye Drops
in combination (n=12)
(n) % (n) % (n) %
Poor (<50%) - - 4 33.3% 1 8.3%
Fair (51-69%) - - 1 8.3% 2 16.7%
Good (70-84) 2 20% - - 1 8.3%
Very Good (85-94%) 2 20% - - 1 8.3%
Excellent (95-100%) 6 60% 7 58.3% 7 58.3%
Table 3. Baseline Data
Measure Honey Nasal Spray Honey Nasal Spray + Honey Eye Drops p
SNOT-20 Score 34±19 34±15 0.98
OSDI Score 31±19 38±26 0.46
Temporal Bulbar Redness 1.4±0.3 1.2±0.4 0.49
Nasal Bulbar Redness 1.7±0.5 1.3±0.5 0.014*
Temporal Limbal Redness 1.0±0.5 0.8±0.3 0.18
Nasal Limbal Redness 1.1±0.5 0.8±0.2 0.07
Phenol-Red Thread Test (mm) 9.8±7.5 11.5±8.0 0.61
NIKBUT (s) 11.7±5.4 11.2±6.7 0.84
FBUT (s) 4.7±2.5 4.6±2.4 0.96
Oxford Stain Score 4.6±3.2 3.1±2.7 0.25
*Baseline data significantly different between groups at p ≤ 0.05. 
Data are mean ± SD. Italicized p values represent non-parametric test outcomes. 
Abbreviations: SNOT = Sino-Nasal Outcome Test, OSDI = Ocular Surface Disease Index, NKIBUT = non-invasive tear break up time, FBUT = 
Fluorescein tear break up time.
Perng, et al.: Honey nasal spray for rhinosinusitis and dry eye
J Apither ● 2016 ● Vol 1 ● Issue 2  39
Treatment Effects at 4 weeks
There were statistically significant improvements from 
baseline to 4 weeks in both nasal symptoms and Oxford 
ocular surface staining score for both treatment groups 
(Table 4) (Figure 1 and 2). In addition the honey nasal 
spray eye drop combination group also had significant 
improvement in ocular symptoms (Table 4) (Figure 3). 
There were no statistically significant improvements in the 
other measures and no significant differences between the 
two treatments (See Table 4). 
No important adverse events were recorded in the logbooks. 
As expected, symptoms reported included nasal discharge, 
dry eye and red eyes. Comments indicating improvement 
included “relieves nasal congestion” and “eyes feel 
lubricated”.
Table 4. Treatment Effect of Each Group and their Comparison
Measure Honey Nasal Spray
BL vs Week 
4
p
Honey Nasal Spray 
+ Honey Eye Drops
BL vs Week 4
p
Comparison 
Between Groups
p
SNOT-20 Score -12±15 0.03* -12±18 0.04* 0.21
OSDI Score 0.2±13.2 0.99 -10.8±15 0.03* 0.09
Temporal Bulbar Redness 0.1±0.3 0.48 0.0±0.4 1 0.46
Nasal Bulbar Redness 0.0±0.5 0.80 0.0±0.4 0.87 0.87
Temporal Limbal Redness 0.0±0.3 0.57 0.1±0.3 0.79 0.67
Nasal Limbal Redness 0.3±0.5 0.96 -0.1±0.2 0.11 0.16
Phenol-Red Thread Test (mm) -0.3±4.2 0.8 1±7.6 0.66 0.63
NIKBUT (s) 5.5±7.6 0.05 0.5±3.3 0.85 0.18
FBUT (s) 2.6±4.5 0.10 1.3±4.3 0.33 0.49
Oxford Stain Score -2.3±1.4 0.007* -1.3±1.6 0.015* 0.09
Data are mean ± SD. *Treatment effect for each group statistically significant at p ≤ 0.05. 
Italicized p values represent non-parametric test outcomes. 
Abbreviations: SNOT = Sino-Nasal Outcome Test, OSDI = Ocular Surface Disease Index, NKIBUT = non-invasive tear break up time, FBUT = 
Fluorescein tear break up time.
Figure 1. Sino-Nasal Outcome Test (SNOT-20) scores at baseline 
and following 4 weeks of treatment in the Honey Nasal Spray and 
Honey Nasal Spray + Honey Eye Drops treatment groups. Data are 
mean ± SD. * Indicate differences between baseline and week 4 
significantly different at p<0.05. 
Figure 2. Oxford Ocular Surface Stain Scores at baseline and 
following 4-weeks of treatment in the Honey Nasal Spray and Honey 
Nasal Spray + Honey Eye Drops treatment groups. Data are mean ± 
SD. * Indicate differences between baseline and week 4 significantly 
different at p<0.05. 
Figure 3. Ocular Surface Disease Index (OSDI) scores at baseline 
and following 4-weeks of treatment in the Honey Nasal Spray and 
Honey Nasal Spray + Honey Eye Drops treatment groups. Data are 
mean ± SD. * Indicate differences between baseline and week 4 
significantly different at p<0.05. 
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DISCUSSION
Our finding of improvement in nasal symptoms (with the 
SNOT-20 questionnaire) in rhinosinusitis suffers using 
a honey nasal spray for 4 weeks, supports the findings of 
Thamboo et.al [17] who also reported improved symptoms 
in allergic fungal rhinosinusitis sufferers using a 50% 
Manuka honey over a similar time frame. Their study 
involved using one nostril as a control, i.e. the nasal spray 
was only applied to one nostril.  Leptospermum spp. honey, 
has been demonstrated to be safe, non-toxic and to have 
both antimicrobial and anti-inflammatory effects on the 
ocular surface mucosa when applied undiluted topically in 
dry eye disease [22, 31], and diluted (16.5% to 50%) to the 
sino-nasal mucosa in rhinosinusitis [17, 32].  
The mechanisms by which nasal symptomatic improvements 
were achieved with the honey nasal spray remains to 
be investigated. Bacterial biofilms are thought to play a 
significant role in the pathogenesis of chronic rhinosinusitis 
[33].  Manuka (Leptospermum scoparium) honey has shown 
strong anti-biofilm activity against S. aureus. [14] This 
effect has been shown to be primarily due to uniquely 
high levels of the phenol compound, methylglyoxal 
(MGO), within Manuka Honey [34-35]. Jervis-Bardy et 
al. [15] demonstrated a synergistic anti-biofilm effect 
when augmenting Manuka Honey with additional MGO, 
requiring 16.5% wt/vol Manuka Honey with 0.53 mg/mL 
MGO to achieve complete S. aureus biofilm eradication. 
Further studies have shown that the MGO concentration 
required for anti–S. aureus biofilm activity ranged between 
0.5 and 3.6 mg/mL [36]. 
Thamboo et al. [17]  qualitatively assessed ethmoid cavity 
swabs pre and post one month of nasal Leptospermum spp. 
honey spray treatment but did not find any consistent 
treatment effect of honey. We did not perform nasal 
swabs for colony forming units in this study but have 
previously demonstrated topical application of pure 
Leptospermum spp. honey applied to the conjunctival 
sac thrice daily significantly reduced conjunctival  and 
lid margin (predominantly Staphylococcal spp.) colony 
counts in individuals with dry eye disease [31]. Further 
studies are required to determine if topical ocular and/
or nasal inhalation of medical grade Leptospermum spp. 
honeys impact the nasal mucosal flora and the optimal 
concentrations at which these effects are achieved.
We found a statically and clinically significant improvement 
[37] in dry eye symptoms (OSDI after 4 weeks) in the 
group using the combined honey nasal spray eye drop 
treatment but not the nasal spray alone. Honey eye drops 
used over similar timeframe have been demonstrated to 
improve dry eye symptoms and signs [31, 38]. This may 
mean that the eye drop product needs to be added to 
control dry eye symptoms and that the nasal spray alone 
is not helpful in dry eye. Alternately it may indicate that a 
longer time frame is needed to observe an improvement in 
eye symptoms from using just a honey nasal spray. Given 
the connection between the eye and the nose [5], effects 
of indirect treatments would be expected, but it would 
not be surprising if these were slower to observe.  It would 
also be useful to determine if honey eye drops alone have 
effects on nasal symptoms in sufferers of both dry eye and 
rhinosinusitis.
Dry eye patients have high prevalence of symptoms of 
ocular allergy due an insufficient tear and/or unstable tear 
film prolonging contact of allergens and irritants incident 
on the ocular surface [39]. Our participant group was 
characterised by both a borderline tear deficiency and poor 
tear film stability. Previous studies have demonstrated 
that intranasal steroidal sprays can improve symptoms of 
season and perennial ocular allergy (tearing, redness and 
itch) [40]. One proposed mechanisms for this effect is that 
inhaled allergens and irritants may induce ocular symptoms 
by means of the naso-ocular reflex and it is thought that 
these intranasal steroids hinder the development of allergic 
ocular symptoms by inhibiting the initiation of the naso-
ocular reflex [40]. Another proposed mechanism is that 
intranasal steroids also decrease nasal inflammation and 
oedema in the inferior portion of the nasolacrimal duct, and 
may allow for improved drainage of ocular secretions and 
decreased ocular exposure to allergens and inflammatory 
mediators [40]. Whilst ocular symptomatic improvements 
were not achieved with use of  lone honey nasal spray 
treatment, there were statistically and clinically significant 
improvements [30] in corneal staining in both treatment 
groups; suggesting that there were ocular benefits of the 
lone honey nasal spray treatment.  The improvement in the 
integrity of the corneal epithelium adds to the growing body 
of evidence that some honeys, including Leptospermum 
spp. honeys can improve corneal epithelial integrity [22] 
and promote corneal epithelialisation [41, 42].  
In this study, poorer adherence to dual honey eye drop and 
nasal spray treatment was reported by our participants. 
Adherence to home-based dry eye therapies is traditionally 
poor, particularly where the regime is prolonged or time 
consuming [4, 43]. Whilst twice daily instillation of two 
topical treatments arguably does not require significant 
effort, our middle aged to elderly participants may well have 
been managing multiple other chronic medical issues with 
home-based treatments in addition to participation in this 
study. On average, patients with chronic medical conditions 
take from 30% to 70% of the prescribed medication doses 
and on average 50% discontinue medications in the 
first months of therapy [44]. The glaucoma ophthalmic 
literature shows similarly low rates of adherence to 
treatment [45]. Similar to topical glaucoma eye therapy, 
instillation of both the honey drops and the nasal spray 
typically induces temporary local irritation which is likely 
to most adversely affect the compliance of dual therapy. 
Nevertheless, medically regulated Leptospermum spp. 
antibacterial honey products have numerous practical 
advantages in the chronic care of dry eye and rhinosinusitis: 
low cost, over-the-counter, sterile, non-benzalkonium 
chloride preserved, non-cytotoxic with frequent dosing and 
long term dosing, multi-dose, broad spectrum, unaffected 
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by room temperature and UV and extended shelf life [22, 
46-49]. 
Limitations of this study were the relatively small study 
population (n=22) and short treatment duration (4 weeks), 
and lack of inclusion of a lone honey ocular treatment 
arm. Longer treatment durations of 3 months in a larger 
group of participants would be required to assess changes 
in ocular and nasal clinical signs with honey treatments in 
individuals with concurrent dry eye and rhinosinusitis. As it 
is not possible to mask the treatment from the participants 
it is possible that some of the subjective improvement in 
symptoms was due to a placebo effect.
CONCLUSIONS
Manuka honey nasal sprays appear to be a promising safe 
and low cost remedy for improving symptoms of chronic 
rhinosinusitis. 
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